Welcome to the 2026 Aquestive Therapeutics, Inc. Annual Meeting of Stockholders. Please note that today's meeting is being recorded. I will now turn the meeting over to the Chair of the Board of Directors of Aquestive Therapeutics, Inc., Dr. Gregory Brown.
Thank you. Good morning. My name is Dr. Gregory Brown. I am the Chair of the Board of Directors of Aquestive Therapeutics, Inc. I welcome you to our annual stockholders meeting and call the meeting to order. The agenda for this meeting and the rules of conduct are available on the virtual meeting site. We ask that you please abide by these rules of conduct during this meeting. There will be no separate management presentation following the conclusion of the formal portion of the annual meeting. Following the formal portion of the meeting, we will offer a general question and answer session. Stockholders of record may submit comments or questions at any time during the meeting by utilizing the Ask a Question section located at the bottom left of the page on the virtual meeting site. Shareholders can select a topic and then submit their questions and comments.
In addition to submitting questions during the audiocast of our annual meeting, stockholders are reminded that they are welcome at any time to contact our investor relations team with any questions, concerns, or comments that they may have. Contact information for our investor relations team may be accessed by clicking on the Aquestive logo at the top left of the page on the virtual meeting site, or by visiting investorrelations@aquestive.com. Attending today's virtual meeting, in addition to myself, are our other directors of the Board. Our directors participating in today's annual meeting, in addition to myself, are Dan Barber, Chief Executive Officer of the company, John Cochran, Abigail Jenkins, Dr. Julie Krop, Timothy Morris, and Dr. Marco Taglietti. Also participating, in addition to Mr. Barber, are several other members of our senior leadership team.
These include Peter Boyd, our Chief People Officer, Lori Braender, our Corporate Secretary, Dr. Melina Cioffi, our Senior Vice President, Regulatory Affairs, Dr. Matthew Davis, our Chief Development Officer, Cassie Jung, our Chief Operating Officer, Sherry Korczynski, our Chief Commercial Officer, Dr. Matthew Greenhawt, our Chief Medical Officer, Ernie Toth, our Chief Financial Officer, and Tom Zalewski, our Chief Legal Officer and Chief Compliance Officer. Also in attendance at this annual meeting are representatives from KPMG LLP, the company's independent public accounting firm, Lindsay Phillips and Lauren Smith. As well as Ken Frank, our Inspector of Elections, and representatives from our host, Broadridge Financial Solutions. At this time, I would like to turn the meeting over to our CEO, Dan Barber.
Thank you, Dr. Brown. I would like to take this opportunity to thank all of our board members, our officers, and all of our other colleagues for their continued dedication, commitment, and leadership throughout this past year. We are quickly approaching our ninth year as a public company and are proud of what we have accomplished during that time. This is truly the most exciting time in the history of Aquestive. We have progressed the company significantly and the momentum continues to build as we work towards FDA acceptance of our NDA for our lead product candidate, Anaphylm dibutepinephrine sublingual film, which, if approved by the FDA, will be the first and only non-device-based oral medication indicated for the treatment of severe allergic reactions, including anaphylaxis. We anticipate resubmitting our application to the FDA in the third quarter of this year.
As we work towards resubmission, we are shifting more and more of the company's attention towards ensuring a successful commercial launch of Anaphylm as early as possible in 2027, if approved by the FDA. Among patients and caregivers, we will focus on growing awareness of the ability to easily carry Anaphylm. If approved by the FDA, Anaphylm is the only product that allows for not just one, but two doses to easily fit on the back of your phone, into a wallet or a small purse, providing patients with epinephrine that can be with them anytime, anywhere. From a commercial preparedness perspective, we have built a team of the right people, including a strong medical affairs presence, developed a robust pre-launch awareness platform, utilized our existing payer relationships to prepare for patient access for Anaphylm, built our product messaging and advertising, and established significant relationships with key advocacy groups.
We will continue to build this momentum throughout the remainder of 2026 and expect to launch Anaphylm with a 75-person sales force. Our momentum also continues to build on a global scale, with advancing regulatory interactions in the U.K., Europe, and Canada, confirming that no further clinical work is necessary in these regions for submitting an application of Anaphylm. If approved in each of these regions, Anaphylm could be available to almost 1 billion people in the next couple of years. On our evolving pipeline front, we are utilizing our epinephrine prodrug platform, AdrenaVerse, to advance treatment in other possible indications.
Our lead asset is AQST-108, and we recently completed a phase I safety study in men with androgenic alopecia with no drug-related adverse events and no appreciable systemic absorption observed. Our early biomarker data showed promise, and we will share more on the next studies for AQST-108 once we have resubmitted our Anaphylm application in the U.S. It is a testament to the Aquestive team that they were able to complete so much important work in this past year. Now is a great time for Aquestive. With that, I would like to ask Lori Braender, as Corporate Secretary of the company, to please proceed with the order of business and the agenda for this meeting.
Thank you, Dan. Today's meeting is being hosted by Broadridge on its virtual meeting platform, which allows real-time voting during the meeting. During today's meeting, stockholders of record have the opportunity to vote their shares until we announce that the polls have closed. Most of you will have already voted online or by telephone or submitted your proxy card, and we thank you for doing so. Stockholders who have already voted do not need to vote again today at this meeting. However, if you are a stockholder attending this meeting and you have not yet voted your shares or submitted your proxy, or if you wish to change your previous vote or submitted proxy, you may do so by clicking the Voting button and submitting your vote. Mr. Frank, a representative of the Carideo Group, has been appointed as the Inspector of Elections and vote tabulator for today's meeting.
Broadridge has confirmed that the notice of this meeting and notice of internet availability of proxy materials was sent to each stockholder of record as of April 13th, 2026. The Inspector of Election reports that at least 80,061,326 shares, or approximately 64% of the outstanding stock of the company, are present in person or represented by proxy at this meeting. A quorum is therefore present, and the meeting is properly convened. I will outline our agenda for today's meeting. First, we will vote on the three matters presented to stockholders as detailed in the company's 2026 proxy statement. After the voting and announcement of the preliminary results of the voting, we will close the formal meeting, and we will address any questions which have been submitted by stockholders to this meeting in accordance with the company's rules of conduct.
We will now proceed with the business of this meeting. Each of the three proposals to be acted on today is discussed in the proxy statement. They are, first, the election of the Class II directors, Dr. Gregory Brown, John Cochran, and Abigail Jenkins. Second, the approval on an advisory basis of the compensation of our named executive officers as described in the proxy statement. Finally, for the ratification of the appointment of KPMG LLP, the company's independent public accounting firm for the current fiscal year. If there are any questions on any of these three proposals, please submit them now on the virtual screen by using the Ask a Question section on the bottom left of the screen. At this time, we ask that you confine your questions to the three specific proposals included in the proxy statement and subject to vote at this meeting.
A general question and answer period will follow the formal part of this meeting for other questions. There being no questions submitted on the proposals to be voted on, we will now proceed to take the vote on these three matters. If you have already submitted a valid proxy, you need not vote now at this meeting. Your votes will be cast as indicated on your proxy card, voting instruction form, by form, or online. The proxies have already cast their vote with the Inspector of Election. You may now vote your shares if you wish and have not already done so during this meeting. The voting is now concluded, and the polls are now closed. The Inspector of Election has provided a preliminary report on the voting.
First, the Inspector of Elections reports that the persons nominated for director, Dr. Gregory Brown, John Cochran, and Abigail Jenkins, have received at least 36 million votes, representing at least 86% of the votes cast in the election, and therefore have been elected as the Class II directors of the company. The second proposal relating to the non-binding advisory vote on the compensation of our named executive officers has received the favorable vote of not less than 92% of votes cast on this proposal, and therefore this proposal has been approved on an advisory basis. The third proposal relating to the ratification of the appointment of KPMG as the company's independent public accounting firm for the current fiscal year has received the favorable vote of not less than 98% of the votes cast on this proposal, and therefore this proposal has been approved.
We will report the final tally of all votes on the Form 8-K, which will be filed with the Securities and Exchange Commission within four business days of this meeting. That concludes our agenda. I will turn the meeting back over to Dan.
All formal business is now concluded. We therefore close and adjourn the formal part of the meeting. At this time, we will hold a general question and answer session. As a reminder, if you logged into the meeting as a stockholder with your 16-digit control number and not as a guest, then you are able to ask a question by using the Ask a Question section at the bottom left of your screen. Because this annual meeting is not being publicly webcast, nothing discussed today is intended to or should be understood to provide any material non-public information over and above or different from what we have previously publicly disclosed or to update any previous publicly disclosed material information.
As a consequence, any questions submitted in today's meeting that request or would require a response disclosing material non-public information or an update of any previously publicly disclosed material information will not be answered today. We look forward to providing you an update during our next earnings call in August. Showing no questions. If there are no questions at this time, on behalf of the members of our board of directors and officers of the company, I would like to thank you all for attending today's meeting. We look forward to having you participate in next year's annual meeting.
This concludes the meeting. You may now disconnect.